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SUMMARY
Objective: The aim of the present study was to examine serum cystatin C levels in association with the Mediterranean diet in a healthy Greek 
population.
Methods: Cystatin C together with basic clinical chemistry tests was measured in a total of 490 adults (46 ± 16 years, 40% of males), who un-
derwent an annual health check. Demographic, anthropometric and lifestyle characteristics were recorded, while adherence to the Mediterranean 
diet was evaluated through the MedDietScore (0–55). 
Results: The mean level of serum cystatin C was 0.84 mg/L, while men had increased serum cystatin C levels compared to women (0.86 mg/L 
vs. 0.83 mg/L, respectively, 0.017). After adjusting for age, gender, body mass index, smoking status, hypertension, diabetes, hypercholestero-
lemia, estimated glomerular filtration rate (eGFR), albumin and ferritin levels, each unit increase in MedDietScore led to 0.002 mg/dL drop off in 
cystatin C serum levels.
Conclusions: We have demonstrated an inverse relationship between the MedDietScore and serum cystatin C levels. Our finding that increases 
in MedDietScore are associated with decreases in serum cystatin C levels could imply that adherence to the Mediterranean diet may reduce the 
cardiovascular risk, as assessed by cystatin C, a prognostic marker of the cardiometabolic risk. This notion could have a great impact on public health.
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INTRODUCTION
Cystatin C is a non-glycosylated, low molecular weight (13.250 
Da), basic protein that is a member of the cystatin superfamily 
of cysteine protease inhibitors (1–3). It consists of 120 amino 
acids, it is produced by all nucleated cells at a constant rate, and 
it is excreted by the kidneys by free glomerular filtration and 
complete tubular reabsorption and degradation (4–6). Besides 
its usefulness as a marker of renal function, serum cystatin C 
appears to be a prognostic marker of cardiovascular events and 
death among elderly persons without chronic kidney disease (7, 
8). The association of serum cystatin C with chronic low-grade 
inflammation and atherosclerosis has been proposed as the causal 
link between increased cystatin C concentrations and adverse 
cardiovascular outcomes (9).
As widely known, dietary habits play a critical role in the 
pathogenesis of atherosclerosis. The present study aimed to ex-
plore whether there is an association between the Mediterranean 




Between April 2009 and January 2010, a total of 490 con-
secutive adults (46 ± 16 years, 40% of men) who had visited the 
Polyclinic of General Hospital for a health check-up, agreed to 
participate in the study (85% of participation rate). The retrieved 
data were confidential and the study followed the ethical con-
siderations provided by the World Medical Association (52nd 
WMA General Assembly, Edinburgh, Scotland, October 2000). 
Moreover, the Institutional Review Board approved the design, 
procedures and aims of the study (GA 23/14.05.2009). All partici-
pants were informed about the procedures of the study and agreed 
to participate providing written informed consent.
Lifestyle and Anthropometric Measures
All the participants were Caucasians. Information on age 
(years), gender (males vs. females), level of education (years 
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of school) and family status (singles, i.e. single, divorced, 
widowed, vs. married) were recorded in a self-administrated 
questionnaire.
With respect to lifestyle characteristics, participants were 
asked to fill in a 10-grade scale range regarding their physical 
activity status (grade of scale used: 1–10, where 1 denotes sed-
entary lifestyle and 10 daily hard activity of at least 30 minutes). 
Participants with score ≤ 7 were classified as of low/moderate 
activity, while those with score > 7 were considered as highly 
active. Current smoking was defined as smoking at least 1 ciga-
rette/day for the past year. The number of cigarettes per day and 
the total years of smoking were also recorded. A 76-item valid 
semi-quantitative Food Frequency Questionnaire (FFQ) was used 
to record participants’ dietary habits (10). Alcohol consumption 
was then assessed as the number of drinks per day measured in 
equivalences of ethanol intake. Furthermore, overall assessment 
of dietary habits in terms of adherence to the Mediterranean 
dietary pattern was evaluated through the MedDietScore (range 
0–55) (11). Higher values of the score indicate greater adherence 
to this pattern and, consequently, healthier dietary habits. More 
specifically, one unit increase in MedDietScore could reflect 
small dietary modifications such as consumption of 1 more fish 
serving per week, 3 more fruits per week, or consumption of 1 
less portion of red meat per week. The top score of MedDietScore 
(i.e. 55) depicts the strongest adherence to the Mediterranean diet 
which consists of more than 4 portions of non-refined cereals per 
day, more than 5 potatoes a week, 3 fruit and 4 vegetables por-
tions a day, more than 6 fish and legumes servings per week, and 
everyday use of olive oil in cooking. Moreover, the highest score 
includes moderate alcohol intake, modest consumption of full-fat 
dairy (less than 10 servings per week) and poultry (maximum 3 
portions per week), while red meat intake should not exceed 1 
serving per week.
Waist circumference and height were measured to the nearest 
0.5 cm, without shoes, and weight was measured with a lever 
balance to the nearest 100 g without shoes in light undergarments. 
Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in metres. Participants were clas-
sified as overweight if BMI was between 25–29.9 kg/m2, while 
obesity was defined as BMI greater than 29.9 kg/m2.
Systolic and diastolic blood pressure was measured twice in 
all participants by the same physician using a standard mercury 
sphygmomanometer on the right arm of the seated subject. The 
mean value for blood pressure measurements was adopted. Hy-
pertension was thus defined as a systolic blood pressure ≥ 140 
mmHg and/or a diastolic blood pressure ≥ 90 mmHg or the use 
of anti-hypertensive drugs. Coronary heart disease, heart failure, 
cerebrovascular disease, and peripheral arterial disease were as-
sessed by self-report and medication use. Diabetes was assessed 
by self-report, medication use or a positive diagnosis by fasting 
blood glucose level (≥ 126 mg/dL) (12). Hypercholesterolemia 
was defined as a serum cholesterol ≥ 200 mg/dL or by the use of 
cholesterol-lowering drugs.
Laboratory Parameters
Venipuncture was performed for each participant early in 
the morning (between 7 a.m. to 11 a.m.), after a 12-hour fasting 
period by applying a natural latex rubber strap and using a 20 mL 
syringe. Reproducibility in the lab has been determined using hu-
man samples and controls in an internal protocol. For the above 
mentioned tests, within run and between day coefficients of vari-
ation (CV) were less than 7%. Accuracy of results was further 
supported by participation in suitable external quality assurance 
programmes (ESEAP). All measurements were performed on a 
Roche/Modular Analytics analyzer. Reagents, calibrators, con-
trols, and consumables were purchased from the same supplier 
(Roche Diagnostics GmbH, Mannheim, Germany).
Statistical Analysis
Continuous variables are presented as mean values ± standard 
deviation under the normal distribution hypothesis and me-
dian (1st, 3rd quartile) for not normally distributed continuous 
variables. Categorical variables are presented as frequencies 
(relative frequencies). Independent samples t-test, or the non-
parametric Mann-Whitney U-test were used in the unadjusted 
analyses (where appropriate). Multiple regression analyses 
were performed in order to test the associations between the 
MedDietScore and serum levels of Cystatin C, after control-
ling for several confounders in three nested models. Results are 
presented as Beta coefficients. All reported p-values are based 
on two-sided tests and compared to a significance level of 5%. 
SPSS 18.0 software (SPSS Inc. 2004, Chicago, Illinois, USA) 
was used for all statistical calculations.
RESULTS
The mean level of serum cystatin C was 0.84 mg/L, while 
men had increased serum cystatin C levels compared to women 
(0.86 mg/L vs. 0.83 mg/L, respectively, 0.017). The mean level 
of adherence to the Mediterranean diet was moderate (i.e. 30/55 
as assessed using the MedDietScore), but it was at the same level 
for both genders (p = 0.329). The socio-demographic and clini-
cal characteristics of the participants are presented in Table 1, in 
respect to their gender.
As presented in Table 1, men had significantly higher Body 
mass index than women, higher waist circumference, higher 
systolic and diastolic blood pressure, higher serum glucose 
levels, higher serum triglycerides levels, higher cystatin C 
levels, higher serum albumin levels, and higher ferritin lev-
els, while they had lower HDL-cholesterol levels and lower 
glomerular filtration rate (GFR) than women. In order to bet-
ter evaluate the effect of adherence to the Mediterranean Diet 
on cystatin C serum levels three nested models adjusted for 
several socio-demographic and clinical characteristics were 
performed (Table 2).
After adjusting for age, gender, body mass index, and smok-
ing status, each unit increase in the MedDietScore led to 0.003 
mg/dL reduction of cystatin C levels (Model 1). After further 
adjustment for the presence of hypertension, diabetes and hy-
percholesterolemia, each unit increase in the MedDietScore led 
to a 0.003 mg/dL decrease of cystatin C levels (Model 2). In the 
final model (Model 3), three more confounding factors were taken 
into account (i.e. GFR, albumin and ferritin levels). Even in this 
model, each unit increase in the MedDietScore led to 0.002 mg/
dL drop off in cystatin C serum levels (Model 3).
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DISCUSSION
In this study, we observed an inverse relationship between 
adherence to the Mediterranean diet and serum cystatin C levels 
after adjustment for age, gender, body mass index, smoking habits, 
hypertension, diabetes, and hypercholesterolemia. In other words, 
adherence to the Mediterranean diet was associated with lower 
serum cystatin C levels.
Cystatin C is produced by all nucleated cells at a constant rate, 
and it is excreted by the kidneys by free glomerular filtration and 
complete tubular reabsorption and degradation (13, 14). Therefore, 
serum concentration levels of cystatin C are almost totally depend-
ent on the glomerular filtration rate and even a slight reduction in 
glomerular filtration rate causes a rise in serum cystatin C (15, 16). 
Besides its usefulness as a marker of renal function, serum cystatin 
C appears to be a prognostic marker of cardiovascular events and 
death among elderly persons without chronic kidney disease (17, 
18). In recent years, cystatin C has emerged as a potential marker 
for cardiovascular risk (18, 19). A plausible link between increased 
cystatin C concentrations and adverse cardiovascular outcome 
apart from renal failure could be chronic inflammation such as 
atherosclerosis. Indeed, high serum cystatin C concentrations have 
been documented to be associated with high concentrations of 
hs-CRP and monocytes count in blood (20, 21). In fact, the mono-
Characteristic Men (n = 296) Women (n = 194) p
Age (years) 47 ± 16 46 ± 16 0.342
MedDietScore (0–55) 30 ± 4 30 ± 4 0.329
Body Mass Index (kg/m2) 28 ± 4 26 ± 5 < 0.001
Waist circumference (cm) 99 ± 12 87 ± 13 < 0.001
Systolic blood pressure (mmHg) 123 ± 17 116 ± 19 < 0.001
Diastolic blood pressure (mmHg) 77 ± 11 72 ± 11 < 0.001
Glucose (mg/dL) 101 ± 18 94 ± 16 < 0.001
Total cholesterol (mg/dL) 200 ± 43 200 ± 38 0.612
HDL-cholesterol (mg/dL) 43 ± 11 55 ± 14 < 0.001
LDL-cholesterol (mg/dL) 130 ± 39 127 ± 34 0.257
Triglycerides (mg/dL) 118 (82, 161) 80 (59,116) < 0.001*
C-reactive protein (mg/dL) 0.10 (0.10, 0.20) 0.10 (0.00, 0.28) 0.755*
Cystatin C (mg/dL) 0.86 ± 0.16 0.83 ± 0.16 0.017
Glomerular Filtration Rate (mL/min) 102 ± 18 107 ± 20 0.016
Albumin (g/dL) 4.8 ± 0.28 4.6 ± 0.28 < 0.001
Ferritin (ng/dL) 128 ± 90 65 ± 80 < 0.001
Table 1. Socio-demographic and clinical characteristics of the participants in respect to their gender (N = 490) 
Continuous variables are presented as mean ± standard deviation when normally distributed (and median (1st ,3rd quartile)); p-values obtained from independent samples; 
t-test under the normal distribution hypothesis (and Mann-Whitney non parametric test if normality was not satisfied) 
Characteristic
Beta (95% CI)
Model 1 Model 2 Model 3
Age (years) 0.005 (0.004,0.006) 0.005 (0.004,0.006) 0.001 (0.000,0.002)
Gender (male vs. female) 0.023 (−0.004,0.049) 0.024 (−0.003,0.050) 0.005 (−0.013,0.022)
MedDietScore (per 1 unit out of 55) −0.003 (−0.007,0.000) −0.003 (−0.006,0.000) −0.002 (−0.004,0.000)
Body Mass Index (per 1 kg/m2) 0.001 (−0.002,0.004) 0.001 (−0.002,0.004) 0.000 (−0.002,0.002)
Smoking (yes vs. no) 0.040 (0.013,0.068) 0.043 (0.016,0.071) −0.012 (−0.028,0.005)
Hypertension (yes vs. no) - 0.037 (0.004,0.071) 0.004 (−0.015,0.023)
Diabetes (yes vs. no) - −0.020 (−0.071,0.031) 0.004 (−0.025,0.033)
Hypercholesterolemia (yes vs. no) - -0.034 (−0.061,-0.006) −0.012 (−0.029,0.005)
Glomerular filtration rate (per 1 mL/min) - - −0.007 (−0.007,−0.006)
Albumin (per 1 g/dL) - - −0.023 (−0.055,0.010)
Ferritin (per 1 ng/dL) - - 0.000 (0.000,0.000)
Table 2. Nested multivariate linear regression models evaluating the role of adherence to the Mediterranean Diet in serum 
levels of Cystatin C 
Betas estimated through linear regression models
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cyte count in blood has been found to be a better cross-sectional 
marker of plaque presence than hs-CRP, interleukin-6 and WBC 
(22). Monocyte count has recently been demonstrated to be an 
independent predictor of future plaque formation (23). There is 
evidence that elastolytic cysteine proteases and their inhibitors, an 
important one being cystatin C, are involved in the pathogenesis 
of atherosclerosis. Inflammatory cytokines associated with athero-
sclerosis stimulate the production of lysosomal cathepsins, and 
increased plasma concentrations of cystatin C, a cathepsin inhibitor, 
may reflect an attempt to counterbalance a potentially damaging 
increased elastolytic activity. Studies have reported that human 
cathepsins are expressed in endothelial cells, smooth muscle cells, 
and macrophages, and that they are involved in the composition, 
the progression and the rupture of atherosclerotic plaques (19, 24).
On the other hand, the MedDietScore (0–55) is a means to 
evaluate adherence to the Mediterranean diet. Higher values on the 
score indicate greater adherence to this pattern and, consequently, 
healthier dietary habits (11). Diet is considered an essential perqui-
site of prevention, as its impact on the development of coronary 
heart disease has been demonstrated by many studies so far (25, 
26). Moreover, the athero-protective role of the Mediterranean 
diet is not questioned (27, 28). 
Our finding that increases in the MedDietScore are associ-
ated with decreases in serum cystatin C levels could imply that 
adherence to the Mediterranean diet may reduce the cardiovas-
cular risk, as assessed by cystatin C, a prognostic marker of the 
cardiometabolic risk. This inverse relationship which remains 
significant even after adjustment for age, gender, body mass index, 
smoking habits, hypertension, diabetes, hypercholesterolemia, 
GFR, serum albumin and serum ferritin levels could have a great 
impact on public health. The notion that adherence to the Mediter-
ranean diet could help to ameliorate public health in respect of 
cardiovascular risk, is of the utmost importance. It seems likely 
that we can do more to decrease our cardiometabolic risk than 
we have ever imagined. 
CONCLUSION
In conclusion, we have demonstrated an inverse relationship 
regarding the MedDietScore and serum cystatin C levels. In other 
words, adherence to the Mediterranean Diet could be a simple 
and inexpensive method to decrease the cardiovascular risk esti-
mated by serum cystatin C levels. Further large-scale studies are 
needed to confirm this inverse relationship which could promote 
public health.
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